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The Role of Biotransformation in Chemical-
Induced Liver Injury
byJerry R. Mitchell,* Wayne R. Snodgrass,* and James R. Gillette*
The role of drug metabolism in chemical-induced liver injury is reviewed. Parameters for
studying the formition of chemically reactive metabolites are discussed and the factors that alter
the formation and covalentbinding ofreactive metabolites are selectively emphasized. Some ofthe
experimental work that led to these concepts is discussed, especially the chemical toxicology of
the hepatic injury produced by acetaminophen, bromobenzene, furosemide, isoniazid and
iproniazid.
An important result of drug metabolism
studies in recent years has been the realization
that many foreign compounds are metabolized by
the liver and certain other tissues to potent
alkylating, arylating, or free-radical inter-
mediates (1-12). Such studies demonstrate how
chemically stable compounds can produce serious
tissue lesions in man and experimental animals,
including neoplasia, hepatic and renal necrosis,
bone marrow aplasia, and other injuries. These
studies frequently demonstrate a role for sulf-
hydryl containing compounds, particularly gluta-
thione, in protecting tissues from such toxic reac-
tions.
Many ofthe initial concepts ofmetabolic activa-
tion were developed during studies of chemical
carcinogenesis; the work of the Millers in the
United States (1,2) and of Magee and co-workers
in England (3) has been especially illuminating.
The realization that the enzyme pathways re-
sponsible for the metabolic activation of car-
cinogens are the same microsomal mixed-function
oxidases that metabolize most drugs and other
xenobiotics led to the concept that drug-induced
tissue lesions might also be mediated through the
covalent binding of reactive metabolites (6-11).
The lack of reactivity of most chemically stable
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drugs and the frequent localization of tissue
damage only in those organs or to those animal
species having the necessary drug-metabolizing
enzymes supported this view.
Obviously, most drugs and foreign compounds
that enter the body are converted to chemically
inert metabolites that are readily excreted into
urine, bile, or air. Thus, it has become important
to identify when toxicities are mediated by chem-
ically reactive metabolites and when they are
caused by chemically inert metabolites. Because
the latter produce their effects by combining
reversibly with receptor sites, their toxicologic
activity usually can be evaluated simply by mea-
suring the concentration of the metabolite in
body fluids (13). When the response is tissue
damage caused by the covalent binding of chemi-
cally inert metabolites to tissue macromolecules,
however, rarely can the relationship between tis-
sue levels of the metabolite and the severity of
the lesion be determined. Indeed, highly reactive
metabolites may exist for only a few seconds or
less and thus will never accumulate in body
fluids.
ParametersforStudyingReactive Metabolites
How then can one readily determine the forma-
tion of such chemically unstable and reactive
metabolites? It seemed possible that there might
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sion and the amount of covalently bound metabo-
lite for any particular drug or chemical. The
covalent binding of the reactive metabolite could
then be used as an index of the formation of the
metabolite. Furthermore, this parameter might
well be the most reliable estimate of the avail-
ability of the metabolite in situ for causing tissue
damage, since much of the metabolite often de-
composes or is further metabolized before it can
be isolated in body fluids or urine. Thus, one ap-
proach to the problem would be to determine
whether radiolabeled drugs administered to ani-
mals over a wide dose range are covalently bound
to macromolecules in target tissues-that subse-
quently become necrotic.
This approach has been used to implicate toxic
metabolites as mediators of the hepatic necrosis
produced in animals by commonly administered
drugs, such as acetaminophen (paracetamol),
acetanilide, phenacetin, furosemide, isoniazid-
acetylisoniazid, and iproniazid, and by chemical
model toxins, such as halobenzenes, furans, thio-
phenes and hydrazines (6-11). These hepatotoxic
compounds covalently bind to tissue marcromole-
cules when administered in vivo. Since they are
chemically stable substances, the finding of a
covalent linkage with macromolecules in their
target tissue, the liver, indicates that they are
converted in the body to chemically reactive in-
termediates. Moreover, autoradiograms show
that the binding occurs preferentially in the
necrotic areas of the liver. Covalent binding can
also be measured quantitatively by extraction of
tissue proteins with organic solvents or by isola-
tion of the radiolabeled material bound to single
amino acids. Pretreatment of animals with in-
ducers of drug metabolism, such as phenobarbi-
tal, or with inhibitors ofdrug metabolism, such as
piperonyl butoxide, cobalt chloride or a-naphthyl-
isothiocyanate (ANIT), similarly alter the rate of
metabolism of the hepatotoxins, the extent of
hepatic binding of radiolabeled metabolites and
the severity ofhepatic necrosis.
Recent work has extended these concepts to in-
clude the acute renal tubular necrosis produced
by acetaminophen and the antibiotic drug, cepha-
loridine (Loridine)(10, 11). Preliminary evidence
suggests that chemically reactive metabolites of
several aminophenol, furan, and thiophene model
nephrotoxins are responsible for the renal dam-
age causedby the compounds (10,11).
Factors that Alter the Formation and Covalent
Bindingof Reactive Metabolites
In some instances, factors that accelerate or
decelerate drug metabolism may affect the for-
mation and covalent binding of reactive me-
tabolites in seemingly unpredictable ways. The
reason for many of these results becomes clear
after perusing the kinetics of covalent binding in
vivo (Table 1) (14). If the conjugates between the
macromolecules and the reactive metabolites are
not rapidly metabolized, then the amount of
covalently bound metabolites will accumulate un-
til all of the drug is metabolized. But it is impor-
tant to realize that the proportion of the dose
which becomes convalently bound is not always
dependent on the rate at which the drug is con-
verted to the reactive metabolite. For example, if
all ofthe parent drug were converted to the reac-
tive metabolite and all of the chemically reactive
metabolite became covalently bound to tissue
macromolecules, then all of the parent drug
would be covalently bound regardless of the rate
at which the drug is converted to its chemically
reactive metabolite or the rate at which the
chemically reactive metabolite combines with the
tissue macromolecules. Thus, inducers and in-
hibitors of drug-metabolizing enzymes do not
result in changes in covalent binding simply
because they change the rate ofdrug metabolism.
Instead they alter the amount of covalent binding
because these changes in rates result in changes
in the proportion of the dose that becomes con-
verted to the chemically reactive metabolite or in
the fraction of the reactive metabolite that be-
Table 1. Important kinetic factors that must be considered
when evaluating pharmacologic and toxicologic effects of
chemically reactive metabolites.
A. Do inducers or inhibitors alter the relative proportion of
the dose thatis converted tothe active metabolite?
B. Do inducers or inhibitors alter the relative proportion of
the reactive metabolitethatbecomes covalently bound?
C. Do other substances change the tissue levels of co-
substrates used in conjugation reactions with the reactive
metabolite?
D. Do high doses of the hepatotoxin itself lead to depletion of
cosubstrates for conjugation reactions with the reactive
metabolite?
E. Are chemically reactive metabolites formed in different
tissues?
F. Do chemically reactive metabolites leave the tissues in
which they are formed?
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not the rate of drug metabolism per se, but the
pattern of metabolism that determines the mag-
nitude ofcovalent binding.
Whether a given amount of covalently bound
metabolite results in toxicity depends on a host of
factors. If the chemically reactive metabolite
reacted only with vitally important macromole-
cules, then there might be a direct relationship
between the amount of covalently bound metabo-
lite and the severity of the lesion regardless of
the tissue in which the covalent bindingoccurred.
It seems likely, however, that the covalent bind-
ing to macromolecules would be rather indiscrim-
inate and that only a portion ofthe total covalent-
ly bound metabolite would be bound to vitally im-
portant macromolecules. Indeed, in some in-
stances the covalent binding to the vitally impor-
tant components of the cell may not even be a
part of the material being assayed. For example,
CC14 is thought to exert its toxic effects by a
peroxidative interaction between its reactive
metabolite and lipids, but this interaction would
not be measured by the methods used to measure
the covalent binding of the reactive metabolite
with tissue proteins. According to this view, the
amount of covalently bound metabolite required
to cause a specific kind of tissue damage, such as
necrosis, willvary with theforeign compound and
the tissue. In order to relate the formation of
reactive metabolites with any given toxicity,
therefore, one must consider at least four kinetic
determinants: (1) the proportion of the dose of
the toxicant that is converted to a chemically
reactive metabolite; (2) the proportion of the
reactive metabolite that becomes covalently
bound to cellular components; (3) the proportion
ofcovalently bound metabolite that is attached to
vitally important cellular components; and (4)the
proportion of such covalently bound metabolite
that cannot be replaced orrepaired rapidly by the
cell. Obviously, the values of covalently bound
metabolite (3) and (4) will vary with the toxicant,
the tissue in which the covalent binding occurs,
and the mechanism oftoxicity. When the product
of (3) and (4) is small, toxicity may not occur even
though considerable amounts ofcovalently bound
metabolites are found in tissues. Conversely,
when the product of (3) and (4) is high, toxicity
may occur when only small amounts ofcovalently
bound metabolite are found in tissues. Thus, the
importance of numerical values of (3) and (4) are
virtually impossible to estimate at this time and
it is apparent that measurement of covalent bin-
ding alone cannot be used to predict whether a
given compound will cause a given kind of tox-
icity. Only by correlating changes in the amount
of covalently bound metabolite with changes in
the incidence and severity of the toxicity can one
determine whether the injury is mediated
through the formation of a chemically reactive
metabolite.
ExperimentalWorkWhich Led toAboveConcepts
The necessity of examining the covalent bind-
ing ofreactive metabolitesin vivo simultaneously
with the determination of tissue injury and the
pattern ofurinary metabolites is evident fromthe
following studies.
Acetaminophen
In therapeutic doses, acetaminophen is among
the safest of all minor analgesics, but in large
overdoses it can produce fatal hepatic necrosis in
humans (15) and experimental animals (16-18). In
mice, it does not cause centrilobular necrosis in
liver unless the dose is greater than about 300
mg/kg (17). Pretreatment of mice or rats with
pheniobarbital or 3-methylcholanthrene, which in-
creases the metabolism of many drugs, markedly
increases the incidence and severity of the
necrosis, whereas prior administration of piper-
onyl butoxide or cobaltous chloride, which in-
hibits the metabolism of many drugs, decreases
the incidence and severity of the toxicity (17).
Although these data suggested the possibility
that the necrosis was caused by a toxic metabo-
lite, they could not reveal whether the metabolite
was chemically reactive or inert.
Studies with radiolabeled acetaminophen
showed that acetaminophen is converted to a
chemically reactive metabolite that becomes con-
valently bound to liver protein (19). Since
pretreatment of mice with phenobarbital in-
creased the amount of. covalent binding to liver
protein, whereas prior administration of pipero-
nyl butoxide or cobaltous chloride decreased it,
the liver necrosis was apparently caused by the
formation ofachemically reactivemetabolite (19).
After subtoxic doses of acetaminophen, there
was very little covalent binding of radiolabel to
liver protein. As the dose was increased to the
toxic range the proportion of the dose that be-
came covalently bound markedly increased, in-
dicating that the rate of metabolism of aceta-
minophen or its reactive metabolite no longer
June 1976 29followed first-order kinetics after toxic doses
(20). The reason for the dose threshold for the
covalent binding and toxicity of acetaminophen
became clear when it was discovered thatthe con-
centration of glutathione was rapidly decreased
after the administration of toxic doses of the
drug. The principal pathways of acetaminophen
metabolism are shown in Figure 1. A small pro-
portion (about 13°h in mice) of a nontoxic dose of
acetaminophen is converted to a reactive metabo-
lite that rapidly combines with glutathione to
form a conjugate that ultimately is excreted as a
mercapturic acid. After the glutathione in the
liver is decreased, however, the steady-state con-
centration of the reactive metabolite markedly
increases and reacts with protein. In accord with
this view, prior administration of diethyl male-
ate, which decreases the glutathione concentra-
tion in liver without causing liver necrosis,
markedly potentiates the liver damage caused by
acetaminophen (20). Moreover, diets that lower
the concentration of glutathione in liver enhance
the toxicity of acetaminophen (21). On the other
hand, the administration of cysteine and cyste-
amine in mice (6, 20, 22) or methionine in rats
(21), which presumably react either directly or in-
directly with the reactive metabolite, prevented
the liver necrosis.
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FIGURE 1. Pathways ofacetaminophen metabolism.
Studies in vitro revealed that pretreatment of
mice with phenobarbital increases the rate of for-
mation of the reactive metabolite (23). However,
this pretreatment does not significantly alter the
biological half-life of acetaminophen in mice (17),
presumably because phenobarbital does not in-
duce the enzymes that convert the drug to its
glucuronide and sulfate conjugates in this strain
of mice. By contrast, prior administration of pi-
peronyl butoxide, which inhibits the covalent
binding in vitro (23), increased the half-life of
acetaminophenin vivo (17).
In hamsters, acetaminophen eauses liver
necrosis in doses as low as 150mg/kg (18, 24). But
unlike the effects of phenobarbital in mice, the
prior administration of phenobarbital to ham-
sters decreases both the covalent binding of
radiolabeled acetaminophen and the liver necro-
sis caused by the drug (24). The reason for this
species difference became clear when it was dis-
covered that phenobarbital pretreatment of ham-
sters did not increase the rate of formation of the
reactive metabolite by liver microsomes, but
markedly decreased the biological half-life of
acetaminophen in vivo by increasing glucuronida-
tion of the drug (24). These findings thus
demonstrate that a pretreatment may have a pro-
found effect on the formation of reactive metabo-
lites and on toxicity even though it does not
markedly alter the activities of the enzymes that
catalyze either the formation or inactivation of
the reactive metabolite.
The effects of 3-methylcholanthrene, diethyl
maleate, piperonyl butoxide, and cobaltous
chloride on acetaminophen-induced liver necrosis
in hamsters (24) were similar to those in rats (17).
The prior administration of 3-methylcholan-
threne to hamsters increased the formation ofthe
reactive metabolite of acetaminophen by liver
microsomes and accelarated the depletion of liver
glutathione, but had little effect on the biological
half-life of acetaminophen in vivo. Accordingly,
3-methylcholanthrene increased both the
covalent binding of radiolabeled acetaminophen
to liver proteins in vivo and the severity of the
liver necrosis. By contrast, piperonyl butoxide
decreased the formation of the reactive metabo-
lite by hamster liver microsomes, decelerated the
depletion of liver glutathione in vivo and in-
creased the biological half-life of acetaminophen.
Despite the increase in the biological half-life of
the drug, piperonyl butoxide still decreased both
the covalent biding of radiolabeled acetamino-
phen and the severity ofthe liver necrosis.
In contrast to its effects in mice and hamsters,
acetaminophen causes only minor liver damage in
rats at doses as large as 1500 mg/kg (16-18, 21),
in guinea pigs in doses as large as 500 mg/kg and
in rabbits in doses as large as 750 mg/kg (18).
Studies with liver microsomes revealed that the
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partially due to low Vmax values for the forma-
tion of the reactive metabolite by those from
rabbits and guinea pigs and an unusally high Km
(acetaminophen) value for its formation by those
from rats (18,23). In accord with these findings
the concentration of glutathione in liver after the
administration of acetaminophen (300 mg/kg, IP)
was only slightly decreased in rats and guinea
pigs (18,23).
Studies on the distribution of the urinary
metabolites of acetaminophen in different animal
species also illustrate the point that species dif-
ferences in the amount of a metabolite formed
from a reactive metabolite (e.g., a glutathione
conjugate) do not always parallel the species dif-
ferences in the amount of covalently bound
metabolite. At low nontoxic doses of acetamino-
phen virtually all of the reactive metabolite is
converted to its mercapturic acid (Fig. 2) (25).
Thus, the fraction of the dose of acetaminophen
that is excreted into urine as the mercapturic acid
under these conditions may be used as an indirect
estimate of the species difference in the fraction
of the dose that is converted to the reactive
metabolite in vivo. When low, nontoxic doses
were administered (50 mg/kg, IP) about 4% of
the dose was excreted as the mercapturic acid in
rats and about 13-15% was excreted as the mer-
capturic acid in mice and hamsters (Table 2).
Thus, species differences in mercapturic acid ex-
cretion at these low doses of acetaminophen par-
allel the species differences in the covalent bind-
ing of the reactive metabolite and the liver
necrosis caused by high doses of acetaminophen.
When a large dose of acetaminophen (400 mg/kg,
IP) was administered, however, the glutathione
concentrations in liver were markedly decreased
in mice and hamsters, which resulted in consid-
erable amounts of covalently bound reactive
metabolite, and thus the proportion ofthe dose of
acetaminophen excreted as the mercapturic acid
was decreased to about 6.5°/ in mice and about
10% in hamsters (Table 2). In contrast, when this
large dose of acetaminophen was administered to
rats, the glutathione concentration in liver was
changed only slightly (Table 2), and thus the pro-
portion of the dose excreted as the mercapturic
acid was the same as that obtained with the non-
toxic dose (about 4%). Thus, the fraction of the
large dose excreted as the mercapturic acid was
similar in rats, mice, and hamsters, but this dose
of acetaminophen caused liver necrosis only in
mice and hamsters.
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FIGURE 2. Effect of dose on the metabolic disposition of
3H-acetaminophen expressed as percentage of urinary radio-
activity (25): (A) normal hamsters; (B) 3-methylcholan-
threne-pretreated hamsters; (C) phenobarbital-pretreated
hamsters; (D) piperonyl butoxide-treated hamsters; MS =
acetaminophen mercapturic acid. Values are means ± SEM
offour observations.
Table 2. Effect of dose of acetaminophen on the urinary ex-
cretion ofits mercapturic acid in various animal species.a
Mercapturic acid, Liver
Species % ofdose necrosis
50 400 650 (400 mg/kg
mg/kg mg/kg mg/kg dose)
Rat 3.6 3.8 3.8 Nob
Mouse 13.3 6.5 - Yes
Hamster 14.2 9.6 5.6 Yes
aData calculated from references (17,18,24,25).
b At doses of 1000 mg/kg, acetaminophen caused liver
necrosis in 2% ofthe animals (17,18).
June 1976 31The point is further illustrated by the effects of
various treatments on the excretion of the
acetaminophen mercapturic acid in hamsters.
Pretreatment with 3-methylcholanthrene in-
creased the excretion of the mercapturic acid
after the administration of a low, nontoxic dose of
acetaminophen (25 mg/kg) to about 26% of the
dose, whereas the prior administration of piper-
onyl butoxide decreased it to about 5% (Fig. 2).
By contrast, the proportion of the dose excreted
as the mercapturic acid after the injection of a
high dose (300 mg/kg) in hamsters pretreated
with 3-methylcholanthrene was only double that
excreted in hamsters pretreated with piperonyl
butoxide, because the proportion of the dose of
acetaminophen excreted as the mercapturic acid
was decreased as the dose of the drug was in-
creased in 3-methylcholanthrene pretreated ham-
sters but was not not changed in hamsters given
piperonyl butoxide (Table 3). But at 300 mg/kg,
acetaminophen caused massive necrosis in all
hamsters pretreated with 3-methylcholanthrene
and only slight damage in those pretreated with
piperonyl butoxide (24).
Table 3. Effect of treatments on the excretion of acetamino-
phen mercapturic acid after different doses of the drug.
Mercapturic acid,
% ofdose
25 300 Liver
Pretreatment mg/kg mg/kg necrosis
Control 14.4 7.0 Moderate
3-Methylcholanthrene 26.3 10.7 Massive
Piperonyl butoxide 5.0 4.3 Minimal
aDatataken from Potter et al. (24)and Jollow et al. (25).
Bromobenzene
Other principles may be illustrated with
studies on the hepatic necrosis induced by halo-
genated hydrocarbons such as bromobenzene.
Although the urinary metabolites of bromoben-
zene were identified many years ago (26,27), re-
cent studies have revealed that nearly all of the
bromobenzene administered to animals is con-
verted to its chemically reactive metabolite,
bromobenzene 3,4-epoxide, by a cytochrome P-
450 enzyme localized mainly in the endoplasmic
reticulum of liver (Fig. 3) (28-30). Some of the
epoxide rearranges nonenzymatically to form 4-
bromophenol. Some is converted to a dihydrodiol
by an epoxide hydratase in liver endoplasmic
reticulum, the dihydrodiol in turn is dehydro-
genated to 4-bromocatechol by an enzyme in the
soluble fraction of liver. But about 70% of the
epoxide formed in rats receiving a nontoxic dose
of bromobenzene (50 ymole/kg) is converted to a
glutathione conjugate by one or more glutathione
transferases in the soluble fraction of liver; the
conjugate is then converted to a mercapturic acid
that is excreted into urine (29,30). Thus, liver in-
jury depends on the relative rates at which bro-
mobenzene 3,4-epoxide becomes covalently
bound to tissue macromolecules or is converted
to 4-bromophenol,3,4-dihydro-3,4-dihydroxybro-
mobenzene, and 3,4-dihydro-3-hydroxy-4-gluta-
thionylbromobenzene (Fig. 3).
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FIGURE 3. Pathways ofbromobenzene metabolism.
As with acetaminophen, there is a dose thresh-
old for the covalent binding of radiolabeled bro-
mobenzene. The proportion of the dose that be-
comes covalently bound to liver proteins in rats
remains relatively constant only until a dose of
1.2 mmole/kg of bromobenzene is administered
and is markedly increased when large doses are
given (29-31). Moreover, centrilobular necrosis in
liver does not occur unless doses larger than the
threshold dose are given. Aswith acetaminophen,
the dose threshold is due to the depletion of
glutathione in liver (29-31). Accordingly, the pro-
portion of the dose of bromobenzene excreted as
the mercapturic acid decreases from about 70%
to about 50% as the dose is increased from the
nontoxic dose to a toxic dose (30). In addition,
pulse-labeling experiments have revealed that
the rate of covalent binding of radiolabeled
bromobenzene is greater when glutathione con-
centrations in liver are low than when they are
Environmental Health Perspectives 32high (29). Furthermore, in vitro experiments
have shown that the rate of covalent binding is
decreased bythe addition ofglutathione (29).
Pretreatment of rats with phenobarbital,
which accelerates the metabolism of bromoben-
zene, increases the severity of the centrilobular
necrosis and the amount of covalently bound
metabolite (28,29,31). Although this finding in-
dicates that the increase in covalent binding of
the radiolabeled metabolite is caused by an in-
crease in the rate of formation of bromobenzene
3,4-epoxide, the reason for the increase in
covalent binding is subtle. Since all the bromo-
benzene is converted eventually to the epoxide
metabolite, an increase in the rate offormation of
the epoxide alone cannot cause a significant in-
crease in the amount of covalent binding unless
the rate of glutathione synthesis and the mobili-
zation ofother nucleophiles in the body is exceed-
ed during the time that the epoxide is being
formed in the body. Owing to the slow absorption
of the toxic dose of bromobenzene from the intra-
peritoneal cavity (30), bromobenzene persists in
the blood for as long as 6-10 hr in rats and hence
considerable amounts of nucleophiles (presum-
ably cysteine and glutathione) may be mobilized
or synthesized. Thus, the steady-state concentra-
tion of the epoxide depends on the rates at which
bromobenzene is absorbed and converted to the
epoxide versus the rate of mobilization of
nucleophiles (Fig. 3).
Another mechanism in addition to glutathione
detoxification is operative. Since pretreatment of
rats with phenobarbital increases the activity of
the epoxide hydratase in liver endoplasmic re-
ticulum (12), the amount of covalent binding
should decrease after phenobarbital when the
availability of glutathione for conjugation is not
rate-limiting, because more of the epoxide should
be detoxified by conversion to dihydrodiols
(Fig. 3). In accord with this view, the pretreat-
ment of rats with phenobarbital decreases the
covalent binding ofradiolabel when low, nontoxic
doses of radiolabeled bromobenzene are adminis-
tered, has little effect on it when intermediate
doses are given and increases it when high doses
are injected (31,32) (Table 4). Thus, the effects of
pretreatments on the covalent binding ofreactive
metabolites may vary with the dose when the
concentrations of cosubstrates for the con-
jugative reactions can become rate-limiting.
In contrast, the pretreatment of rats with 3-
methylcholanthrene decreases both the covalent
binding of radiolabeled bromobenzene to liver
protein and the severity of liver necrosis (30,33).
Table 4. Effect of phenobarbital pretreatment on covalent
binding to mouse liver proteins after different doses of
"4C-bromobenzene.
Covalent binding, nmole/mgprotein Dose,
mmole/kg Untreated Phenobarbital
0.13 0.074 0.027
1.15 0.79 0.99
4.85 0.44 9.83
aData taken from Reid and Krishna (31).
Since the pretreatment does not alter the bio-
logical half-life of bromobenzene in rats (30) and
actually increases the rate of bromobenzene me-
tabolism by liver microsomes (30), the protective
effect cannot be due to a decrease in the rate of
bromobenzene elimination. Studies ofthe pattern
of urinary metabolites in rats receiving a toxic
dose of bromobenzene revealed that treatment
with 3-methylcholanthrene resulted in a decrease
in the mercapturic acid and 4-bromophenol and an
increase in the bromocatechol, bromobenzene di-
hydrodiol and 2-bromophenol (30). Since 2-
bromophenol cannot be formed from the nonen-
zymatic rearrangement of bromobenzene 3,4-
epoxide, it seems likely that 3-methylcholan-
threne induces the formation of a different
epoxide, presumably bromobenzene 2,3-epoxide.
Moreover, the increase in the bromocatechol and
the bromobenzene dihydrodiol fractions at the ex-
pense of mercapturic acids in the urine of
3-methylcholanthrene-treated rats implies that
the epoxide hydratase as well as the cytochrome
P-450 enzyme was induced (30). Furthermore, in
vitro studies revealed that in the absence of glu-
tathione, the rate of covalent binding of radio-
labeled bromobenzene by microsomes from 3-
methylcholanthrene pretreated rats was slower
that that by liver microsomes from untreated
rats even though the rate of bromobenzene me-
tabolism was faster (34). Increasing the forma-
tion of the bromobenzene 2,3-epoxide thus de-
creases the proportion of the dose of bromoben-
zene that is converted to the bromobenzene 3,4-
epoxide, which may be the more reactive aryl-
ating intermediate. At the same time, increasing
the activity of epoxide hydratase decreases the
dependence of hepatocytes on glutathione in the
inactivation of the epoxides and hence decreases
its rate of utilization. When the rate of conjuga-
tion of glutathione is decreased, its concentration
in hepatocytes can be maintained at high levels
by its synthesis and by the mobilization of other
nucleophiles, such as cysteine from body stores.
June 1976 33The net effect is thus a decrease in the covalent
binding and hepatotoxicity ofbromobenzene.
After the administration of radiolabeled bro-
mobenzene, covalently bound radiolabel is found
not only in the liver but also in a number of other
tissues and blood plasma (31). The finding of
covalently bound radiolabel in plasma raised the
possibility that bromobenzene epoxide was suffi-
ciently stable to leave the liver and be carried by
the blood to other organs, although it still was
possible that the covalently bound bromobenzene
metabolites could have been released from dam-
aged cells or associated with newly synthesized
albumin during its passage through the lumen of
the endoplasmic reticulum. On the other hand,
the finding that bromobenzene metabolites be-
came covalently bound during incubation in vitro
with cell free tissue preparations, such as lung
microsomes (32), also suggested that reactive
metabolites of bromobenzene could be formed in
extrahepatic tissues. Since pretreatment of mice
or rats with phenobarbital increased the covalent
binding ofbromobenzene by liver microsomes but
did not affect its rate of covalent binding by lung
microsomes (32), it was possible to determine
whether bromobenzene epoxide was sufficiently
stable to enter the blood by studying the effects
of phenobarbital on the covalent binding ofradio-
labeled bromobenzene in extrahepatic tissues in
vivo. Such studies revealed that phenobarbital in-
creased the covalent binding of bromobenzene to
macromolecules in both lung and liver of mice re-
ceiving toxic doses of bromobenzene (32). It may,
therefore, be concluded that the epoxide of bro-
mobenzene can escape the liver after depletion of
glutathione and can be carried to the lung where
it becomes covalently bound. These studies thus
demonstrated that the finding of an enzyme that
catalyzes the formation of a reactive metabolite
in an extrahepatic tissue does not necessarily
mean that all of a reactive metabolite that be-
comes covalently bound in that tissue is formed
there.
Furosemide
Recently, large doses of this drug were found
to cause massive hepatic necrosis in mice (35). It
is likely that the liver damage is probably caused
by a reactive metabolite because both the necro-
sis and the covalent binding of radiolabeled
furosemide is decreased by inhibitors of drug me-
tabolism, such as piperonyl butoxide, cobaltous
chloride, and a-naphthylisothiocyanate (11,35).
As with acetaminophen and bromobenzene,
there is a dose threshold for the necrosis and the
covalent binding of furosemide. No covalent bind-
ing, necrosis or alteration in the pattern of
metabolism occurred until the dose exceeded 100
mg/kg. Unlike the dose threshold for bromoben-
zene or acetaminophen, however, the threshold
for furosemide is not due to a depletion of glu-
tathione in liver because toxic doses of furose-
mide do not appreciably decrease the glutathione
concentration (11,35). Instead, the threshold is
apparently caused by a change in the proportion
of the dose that is eliminated unchanged as the
dose is increased. At low doses of the drug, most
of it is highly bound to plasma proteins and vir-
tually all of it is eliminated unchanged (11,35). As
the dose is increased, the plasma concentration is
increased to a level that saturates the anionic
binding sites on plasma proteins and the propor-
tion of the dose that is available to the liver for
metabolism is increased (Fig. 4) (11,35). There
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FIGURE 4. Change in tissue distribution of furosemide after
toxic and nontoxic doses to mice: (-) liver; (- -) plasma.
Environmental Health Perspectives 34are two plausible mechanisms which could ac-
count for these unusual effects. In one mechanism
the transport system for the drug into bile may
become saturated as the unbound concentration
ofthe drug is markedly increased after doses that
saturate the binding sites on plasma proteins. As
a consequence more free furosemide is available
to the liver for metabolism. In the other mech-
anism, the rate of elimination of the drug by the
kidney is limited mainly by the blood flow rate
through the kidney (even though the drug is
highly bound to plasma proteins) while the rate of
metabolism by the liver is limited mainly by the
unbound concentration ofthe drug in plasma. Ac-
cording to this view, the saturation of the anionic
sites on the plasma proteins that occurs after the
administration of large doses of furosemide in-
creases the unbound proportion of the drug in
plasma and thus increases the rate of metabolism
of the drug by the liver but does not appreciably
affect its rate of elimination by the kidney. Both
of these mechanisms, however, illustrate how
physiological mechanisms of drug elimination can
affect the pattern ofdrug elimination and thereby
affect the kinetics offormation ofchemically reac-
tive metabolites.
Studies on the in vitro covalent binding of
furosemide to liver microsomes have revealed
that the furan moiety of furosemide is the part of
the molecule that is activated by a cytochrome P-
450 enzyme (Fig. 5). Since furosemide radiolabel-
ed with tritium in the furan moiety was covalent-
ly bound to hepatic microsomes in the presence of
NADPH and air to the same extent as furose-
mide radiolabeled with 35S in its sulfonamide
moiety, the bound metabolite must contain both
parts of the furosemide molecule. When the me-
tabolite protein conjugates isolated from liver
were hydrolyzed under mild acidic conditions
(pH 1.5), which splits furosemide into the methyl
furan and the sulfamoyl anthranilic acid portions,
the covalently bound tritum was retained by the
protein, whereas the covalently bound 35S was
lost. Thus, the metabolic activation must have oc-
curred on the furan ring, possibly through the
formation ofa furan epoxide (Fig. 5).
Isoniazid and Iproniazid
Isoniazid, used in the treatment of tuber-
culosis, causes a liver injury that resembles viral
hepatitis (36,37). Recent evidence indicates that
this toxicity may be mediated by a chemically re-
active metabolite formed from acetylisoniazid,
the major metabolite of isoniazid (Fig. 6). This
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35possibility was suggested by studies of isoniazid
metabolism in which an unusually high propor-
tion of patients with liver injury were found to be
genetically fast acetylators ofisoniazid (36-39).
Studies in rats revealed that acetylisoniazid in
doses greater than 100 mg/kg caused rare, scat-
tered, single cell necrosis in the liver, but after
the animals were pretreated with phenobarbital
these doses caused a marked hepatic necrosis
(9,39,40). Moreover, the necrosis was prevented
by treatment with cobaltous chloride, aminotri-
azole and piperonyl butoxide, suggesting that the
necrosis was caused by a metabolite of acetyl-
isoniazid.
By contrast, the parent compound, isoniazid,
did not cause hepatic necrosis in either untreated
or phenobarbital-pretreated rats, even after
lethal doses. However, the proportion ofthe dose
of isoniazid that is excreted as acetylisoniazid
decreases markedly at doses greater than 100
mg/kg, suggesting that the acetylase becomes
saturated after the administration of large doses
ofthe drug. Consequently, when a large dose was
divided into six 100 mg/kg doses and given hour-
ly, the drug caused acute hepatic necrosis in
phenobarbital-pretreated rats.
The administration of "4C-acetyl labeled
acetylisoniazid to rats resulted in considerable
amounts of covalently bound radiolabel in the
liver of rats (9,39,40). The proportion of the dose
that became covalently bound was increased by
prior treatment of the animals with phenobarbi-
tal and was decreased by treatment with cobal-
tous chloride or aminotriazole. However, no
covalently bound radiolabel was found after the
administration of acetylisoniazid labeled in the
pyridine ring of the drug. Thus, the bound por-
tion of the reactive metabolite originates from
the acetyl moiety, formed endogenously in the
body, rather than from isoniazid itself (Fig. 6).
These findings illustrate the importance of study-
ing the covalent binding of conjugates of foreign
compounds before it is concluded that a given
foreign compound does not form chemically reac-
tive metabolites.
A comparison of the urinary metabolites of
isoniazid and acetylisoniazid in rats revealed that
most of the isonicotinic acid excreted into urine
after the administration of isoniazid must be
formed from acetylisoniazid because the relative
amountsofacetylisoniazid andisonicotinicacidex-
creted into urine were nearly identical after the
administration of either isoniazid or acetylisoni-
azid (11,39,40). Thus, it seems likely that the
liver necrosis in rats is mediated by acetylhydra-
zine or one of its metabolites. Indeed, in pheno-
barbital-pretreated rats, acetylhydrazine caused
midzonal and centrilobular necrosis in doses as
low as 15 mg/kg (9,39,40). Since the necrosis
caused by acetylhydrazine could still be inhibited
by cobaltous chloride, aminotriazole and pipero-
nyl butoxide, however, the acetylhydrazine must
be further activated in the body. In fact, the
covalent binding of radiolabeled acetylhydrazine
by rat liver microsomes is catalyzed by cyto-
chrome P-450 in liver microsomes (39-41).
The liver toxicity caused by iproniazid prob-
ably occurs through a similar sequence of events
(Fig. 6). Like acetylisoniazid, iproniazid under-
goes hydrolysis to isonicotinic acid and a hydra-
zine derivative (3941). The isopropylhydrazine
formed in the body, however, may be more toxic
than acetylhydrazine because the Km value for
covalent binding of isopropylhydrazine by rat
liver microsomes is an order of magnitude lower
than that for acetylhydrazine (41).
Summary
In this paper we have discussed an integrated
approach for relating the formation of chemically
reactive metabolites with the incidence and se-
verity of toxicities caused by foreign compounds.
The approach emphasizes the need to correlate
the findings of several different kinds of studies
including the measurement of the biological half-
life ofthe foreign compound, the quantitative iso-
lation of its urinary metabolites and the deter-
mination of the amount of covalent binding of re-
active metabolites both in vivo and in vitro. It
emphasizes the importance of determining how
various treatments affect these parameters.
Although such data by themselves can neither
predict the toxicity of an unknown compount
without morphometric studies nor elucidate the
mechanism by which cell death occurs, they
nevertheless have served an essential role in
showing that many drugs and other foreign com-
pounds cause liver damage through the formation
of chemically reactive metabolites. The concepts
discussed in this paper have been especially
useful in reconciling seemingly conflicting data
obtained in the different kinds of data. Indeed
without these concepts, the mechanism by which
phenobarbital evokes opposite effects on aceta-
minophen toxicity in mice and hamsters (17,24)
would have been virtually impossible to uncover.
The concepts also predict possible pitfalls in at-
tempting to relate species differences in drug
toxicity with species differences in the pattern of
Environmental Health Perspectives 36urinary metabolites and in the biological half-
lives of foreign compounds. They point out that
studies of covalent binding are useful in identify-
ing reactive metabolites of foreign compounds
and the way in which their formation may be de-
creased. Such studies are also useful in identify-
ing whether there are dose thresholds in the tox-
icity of a given foreign compound and the reasons
for such dose thresholds. It seems likely that
studies of covalent binding will also be useful in
determining whether alterations in the incidence
and severity of various toxicities are due to dif-
ferences in the metabolism of the foreign com-
pound or to changes in the events that follow the
formation of the reactive metabolite. Because of
these complexities, the value of examining the
covalent binding of chemically reactive
metabolites in vivo simultaneously with the
determination of tissue injury and the pattern of
urinary metabolites is apparent when elucidating
mechanisms ofchemically induced tissue lesions.
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